Enzaplatovir

CAS No. 1323077-89-9

Enzaplatovir( —— )

Catalog No. M34242 CAS No. 1323077-89-9

Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 215 In Stock
5MG 259 In Stock
10MG 414 In Stock
25MG 730 In Stock
50MG 1088 In Stock
100MG 1479 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Enzaplatovir
  • Note
    Research use only, not for human use.
  • Brief Description
    Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.
  • Description
    Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection.
  • In Vitro
    Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    JAK/STAT Signaling
  • Target
    STAT
  • Recptor
    RSV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1323077-89-9
  • Formula Weight
    377.4
  • Molecular Formula
    C20H19N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 200 mg/mL (529.94 mM; Ultrasonic )
  • SMILES
    Cc1nocc1C(=O)N1CCN2C(=O)c3cccn3C[C@]12c1ccc(C)nc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Eric A F Sim?es, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Mar;7(1):87-120.?
molnova catalog
related products
  • PM-43I

    PM-43I is a selective inhibitor of STAT5/6 Src Homology 2 (SH2) domain.

  • Pomstafib-1

    The cell-permeable, pivaloyloxymethylester of Stafib-1, which is a potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 44 nM.

  • Suptavumab

    Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.